National Institute on Drug Abuse; Notice of Closed Meeting, 78988 [2022-27956]
Download as PDF
<![CDATA[
78988
Federal Register / Vol. 87, No. 246 / Friday, December 23, 2022 / Notices
Project Clearance Liaison, National Institute
on Drug Abuse, National Institutes of Health.
Dated: December 19, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–27990 Filed 12–22–22; 8:45 am]
[FR Doc. 2022–27956 Filed 12–22–22; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
Dated: December 20, 2022.
Lanette A. Palmquist,
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Substance Abuse and Mental Health
Services Administration
National Institute on Drug Abuse;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
TKELLEY on DSK125TN23PROD with NOTICE
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Advancing Technologies to Improve Delivery
of Pharmacological, Gene Editing, and Other
Cargoes for HIV and SUD Mechanistic or
Therapeutic Research.
Date: January 25, 2023.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Caitlin Elizabeth Angela
Moyer, Ph.D., Scientific Review Officer,
Scientific Review Branch, National Institute
on Drug Abuse, NIH, 301 North Stonestreet
Avenue, MSC 6021, Bethesda, MD 20892,
(301) 443–4577 caitlin.moyer@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
VerDate Sep<11>2014
21:35 Dec 22, 2022
Jkt 259001
Request for comments on the initial
revised draft of the Update to the
Certified Community Behavioral Health
Clinics certification criteria
Substance Abuse and Mental
Health Services Administration.
ACTION: Request for Comments on the
Initial Revised Draft of the Update to the
Certified Community Behavioral Health
Clinics Certification Criteria.
AGENCY:
SAMHSA is seeking public comment
on the initial revised draft of the update
to the Certification Criteria for Certified
Community Behavioral Health Clinics
(CCBHCs). CCBHCs were established
under the Section 223 of the Protecting
Access to Medicare Act of 2014 (PAMA,
Pub. L. 113–93). Section 223 of PAMA
requires the establishment of Medicaid
demonstration programs to improve
community behavioral health services
through the development of CCBHCs.
CCBHCs are required to provide a
comprehensive array of coordinated
services to anyone who requests care for
mental health or substance use,
regardless of ability to pay, place of
residence, or age—including
developmentally appropriate care for
children. PAMA required the
Department of Health and Human
Services (HHS) to develop criteria for
states to use when certifying clinics to
participate in their demonstration
programs. These criteria include six
areas: (1) staffing, (2) availability and
accessibility of services, (3) care
coordination, (4) scope of services, (5)
quality and other reporting, and (6)
organizational authority. The current
Certification Criteria can be found at:
https://www.samhsa.gov/sites/default/
files/programs_campaigns/ccbhccriteria.pdf.
There have been significant
developments in the CCBHC program
and in the broader mental health and
substance use disorder field since the
development of the existing
Certification Criteria. States and
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
providers now have six years of
experience with the CCBHC model and
lessons learned related to the
implementation of the Certification
Criteria. SAMHSA is seeking to make
minor revisions to the Criteria to
respond to these developments and
lessons learned, while still maintaining
the overarching requirements for
program areas and scope of services
outlined in PAMA.
To develop the initial draft of the
updated CCBHC Criteria, SAMHSA
gathered input in several ways. Public
opportunities for input were posted on
https://www.samhsa.gov/certifiedcommunity-behavioral-health-clinics/
ccbhc-criteria-update-announcements.
Public meeting dates and virtual
locations were disseminated through
SAMHSA listservs. On November 17,
2022, SAMHSA held a virtual public
listening session open to the public to
provide input on the existing CCBHC
Criteria. SAMHSA also accepted written
input from the public and stakeholders
sent to ccbhccriteria@samhsa.hhs.gov
by November 21, 2022. In addition to
public outreach, SAMHSA also received
feedback on potential revisions to the
existing CCBHC Criteria from key
stakeholders and federal partners.
The initial draft of the updated
CCBHC Criteria will be available for
public comment before the end of
December 2022 and will be open to midJanuary 2023. Information on CCBHC
Criteria updates and the process to
support them is available at: https://
www.samhsa.gov/certified-communitybehavioral-health-clinics/ccbhc-criteriaupdate-announcements. The posting of
the initial draft of the updated CCBHC
Criteria will also be announced through
SAMHSA’s listserv, CCBHC Training
and Technical Assistance grant
program, and CCBHC State Technical
Assistance contract. SAMHSA requests
all comments to the initial draft of the
updated CCBHC Criteria be sent to
ccbhccriteria@samhsa.hhs.gov.
Authority: Section 223 of the
Protecting Access to Medicare Act
(2014), as amended.
Contact: Mary Blake, Substance
Abuse and Mental Health Services
Administration, 5600 Fishers Lane,
Rockville, MD 20857, telephone (240)
276–1747; email: mary.blake@
samhsa.hhs.gov.
Alicia Broadus,
Public Health Advisor.
[FR Doc. 2022–28028 Filed 12–22–22; 8:45 am]
BILLING CODE 4162–20–P
E:\FR\FM\23DEN1.SGM
23DEN1
]]>Agencies
[Federal Register Volume 87, Number 246 (Friday, December 23, 2022)]
[Notices]
[Page 78988]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-27956]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Advancing Technologies to Improve Delivery of
Pharmacological, Gene Editing, and Other Cargoes for HIV and SUD
Mechanistic or Therapeutic Research.
Date: January 25, 2023.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Caitlin Elizabeth Angela Moyer, Ph.D.,
Scientific Review Officer, Scientific Review Branch, National
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 443-4577 [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: December 19, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-27956 Filed 12-22-22; 8:45 am]
BILLING CODE 4140-01-P
